A5019330655- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Diagnosis and Treatment
- Urological Disorders and Treatments
- Urinary and Genital Oncology Studies
- Ureteral procedures and complications
- Prostate Cancer Treatment and Research
- Infective Endocarditis Diagnosis and Management
- Urologic and reproductive health conditions
- Metabolism, Diabetes, and Cancer
- Cancer, Lipids, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Urinary Bladder and Prostate Research
- Epigenetics and DNA Methylation
- Pelvic and Acetabular Injuries
- Healthcare Systems and Practices
- Health, Medicine and Society
- Colorectal Cancer Surgical Treatments
- Diet and metabolism studies
- HIV/AIDS drug development and treatment
- Pelvic floor disorders treatments
- Renal and Vascular Pathologies
- Cardiac Valve Diseases and Treatments
- Urinary Tract Infections Management
- Cardiac, Anesthesia and Surgical Outcomes
- Minimally Invasive Surgical Techniques
University Hospital of Geneva
2006-2024
University of Geneva
2016-2022
Générale-Beaulieu Clinic
2021
Hôpital Pellegrin
2009-2020
Centre Hospitalier Universitaire de Bordeaux
2013-2020
Université de Bordeaux
2019
Vienna General Hospital
2016-2017
Medical University of Vienna
2016-2017
HES-SO Genève
2016-2017
Comprehensive Cancer Center Vienna
2016
Abstract Metformin inhibits cancer cell proliferation, and epidemiology studies suggest an association with increased survival in patients taking metformin; however, the mechanism by which metformin improves outcomes remains controversial. To explore how might directly affect cells, we analyzed altered metabolism of prostate cells tumors. We found that decreased glucose oxidation dependency on reductive glutamine both lines a mouse model cancer. Inhibition anaplerosis presence further...
Study Type – Therapy (case series) Level of Evidence 4 OBJECTIVE To assess how advances in urology, radiology and orthopaedics are changing the current management bladder ruptures, by reviewing patients treated for ruptures after blunt trauma. PATIENTS AND METHODS Our database was screened admitted with between 1980 2008. Charts were reviewed demographics, clinical variables, diagnostics, treatment outcome. RESULTS Thirty‐six extraperitoneal (EPR, 61%) intraperitoneal (IPR) or combined (39%)...
The objective of this population-based study was to assess patient, physician and tumour determinants associated with positive surgical margins after prostatectomy, the effects on prostate cancer-specific survival. We included 1’254 cancer patients recorded at Geneva Cancer Registry who had radical prostatectomy during 1990–2008. To factors margins, we used logistic regression. assessed survival by Cox proportional hazard models accounting for numerous other prognostics including volume,...
The term close surgical margin refers to a tumor extending the inked of specimen without reaching it. Current guidelines state that should simply be reported as negative. However, this recommendation remains controversial and relies on limited evidence. We evaluated impact margins long-term risk biochemical recurrence after radical prostatectomy.We identified 1,195 consecutive patients who underwent prostatectomy lymphadenectomy for localized prostate cancer at our institution from 1993...
Background: VPM1002BC is a modified mycobacterium Bacillus Calmette Guérin (BCG) for the treatment of non-muscle invasive bladder cancer (NMIBC). The genetic modifications are expected to result in better immunogenicity and less side effects. We report on patient safety immunology first intravesical application human.Methods: Six patients with BCG failure received 6 weekly instillations VPM1002BC. Patients were monitored adverse events (AE), excretion cytokines, respectively.Results: No DLT...
Objective To report on the surgical safety and quality of pelvic lymph node dissection (PLND) in patients treated with radical cystectomy (RC) PLND for muscle‐invasive bladder cancer (MIBC) after neoadjuvant chemo‐immunotherapy. Patients Methods The Swiss Group Clinical Cancer Research (SAKK) 06/17 was an open‐label single‐arm phase II trial including 61 cisplatin‐fit clinical stage (c)T2–T4a cN0–1 operable urothelial MIBC or upper urinary tract cancer. received cisplatin/gemcitabine...
Objective: Urothelial prostatic involvement (UPI) at the time of radical cystoprostatectomy (RCP) was found associated with worse survival outcomes by several previous reports.Our aim is to evaluate impact different levels UPI on using a large series male patients treated RCP.Methods: Whole step section specimens from 995 BCa were assessed for defined as: no vs. urethral carcinoma in situ (CIS) lamina propria ductal CIS prostate stromal involvement.Primary end point study predictors RCP and...
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTFactor S1, a natural corphin from Propionibacterium shermaniiG. Mueller, J. Schmiedl, L. Savidis, G. Wirth, A. I. Scott, P. Santander, H. Williams, N. Stolowich, and KriemlerCite this: Am. Chem. Soc. 1987, 109, 22, 6902–6904Publication Date (Print):October 1, 1987Publication History Published online1 May 2002Published inissue 1 October 1987https://pubs.acs.org/doi/10.1021/ja00256a082https://doi.org/10.1021/ja00256a082research-articleACS...
We assessed the impact of surgical volume on perioperative outcomes and complications robotic extended pelvic lymph node dissection (ePLND).From November 2008 to October 2012, a total 233 consecutive patients with intermediate- or high-risk clinically localized prostate cancer underwent robot-assisted radical prostatectomy (RARP) ePLND by single, experienced open laparoscopic surgeon. Data were prospectively collected. Complications classified according Modified Clavien System. potentially...